MAGED1

Across TCGA pan-cancer cohorts, MAGED1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAGED1 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAGED1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAGED1 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and HNSC are the cancer types where MAGED1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.537	0.832	.001	64	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	18	view →
HNSC	DFS	Tertile	IV	0.559	0.927	.010	13	view →
OV	DFS	Quartile	All	0.512	0.835	.047	8	view →
LUAD	DFS	Median	All	0.529	0.740	.024	2	view →
GBM	OS	Quartile	All	0.721	0.979	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAGED1–CCRCC (DFS)

Open the CCRCC breakdown →